Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

What Faron Pharmaceuticals' (LSE:FARN) Bond Deferral and Trial Plans Mean on the FTSE AIM All Share Index

Faron, which trades as Faron Pharmaceuticals Ltd (Oy in its Finnish form), is a clinical-stage biopharmaceutical company focused on immunotherapy. Its lead candidate, bexmarilimab, is designed to target a receptor on immune cells that tumours can exploit to evade the immune system. The drug …

Ankur Sharma | 15 October 2026

How GENinCode (LSE:GENI) Is Lining Up Key Regulatory Filings on the FTSE AIM All Share Index

GENinCode is a UK-based predictive genetics business focused on the prevention of cardiovascular disease, with an additional interest in ovarian cancer risk. It offers genetic risk tests based on blood or saliva samples through operations in the UK, Spain and the United States. Its …

Ankur Sharma | 15 October 2026

How hVIVO (LSE:HVO) Is Betting on a Second-Half Rebound on the FTSE AIM All Share Index

hVIVO is a contract research organisation best known for human challenge trials, in which healthy volunteers are deliberately exposed to a pathogen in a controlled setting to test vaccines and antivirals. It runs quarantine facilities in London and has broadened its offering into early-phase …

Ankur Sharma | 15 October 2026

Truetide Investors Seek Evidence That Paraytec Progress Can Create Value

The announcement relates to paraytec investment update brings portfolio progress into focus.

Ankur Sharma | 15 October 2026

How ImmuPharma (LSE:IMM) Is Chasing a P140 Partnering Deal on the FTSE AIM All Share Index

ImmuPharma is a UK-listed drug discovery and development company. Its lead asset, P140, is a peptide being explored as a treatment for autoimmune and inflammatory conditions, including lupus, and the company has US licensing partner Avion Pharmaceuticals for the programme. It is also developing …

Ankur Sharma | 15 October 2026

What Is Driving Interest in Aptamer Group (LSE:APTA) on the FTSE AIM All Share Index?

Aptamer Group develops Optimer binders, which are engineered nucleic acid molecules designed to act as alternatives to antibodies. These binders can be used in research tools, diagnostics and therapeutic delivery. The company earns money through fee-for-service discovery programmes for partners in life sciences and …

Ankur Sharma | 15 October 2026

What Investors Should Know About Bioventix (LSE:BVXP) Ahead of Its Full-Year Results on the FTSE AIM All Share Index

Bioventix develops and supplies high-affinity sheep monoclonal antibodies for use in clinical diagnostics. Most of these antibodies are built into tests run on automated blood-testing machines in hospitals and laboratories, supplied by major in-vitro diagnostics companies. The company earns revenue in two ways: from …

Ankur Sharma | 15 October 2026

What Cambridge Nutritional Sciences (LSE:CNSL) Must Fix After a Tough Year on the FTSE AIM All Share Index

The group is a specialist medical diagnostics business focused on food sensitivity and nutrition testing. Its main product lines are FoodPrint, its largest category, the Food Detective rapid test and CNSLab laboratory testing services. It sells in the UK, India, the Americas, Europe, Africa, …

Ankur Sharma | 15 October 2026

Why 4basebio (LSE:4BB) Is Under the Spotlight on the FTSE AIM All Share Index

Based in Cambridge, 4basebio manufactures synthetic DNA using a cell-free, enzymatic process rather than the traditional bacterial plasmid approach. Its main product, opDNA, is designed as starting material for genetic medicines, including gene therapies, genome editing, mRNA production and DNA vaccines. The company holds …

Ankur Sharma | 15 October 2026

How CVS Group (LSE:CVSG) Is Moving On From the CMA Probe as a FTSE 250 Vet Consolidator

For much of the past two years, the shadow of the Competition and Markets Authority's investigation into the UK veterinary market has hung over CVS Group (LSE:CVSG). That chapter has now formally closed. The CMA published its final remedies order on 22 September, and …

Ankur Sharma | 15 October 2026
Support

Hi! How can we help you today?

Loading…